ISCIII

Health Institute Carlos III

Information
Avenida Monforte de Lemos, 5. 28029, Madrid.

pollution, covid-19, rare diseases, epidemiology, immunology, microbiology, AIDS / HIV
Contact
José A. Plaza
Head of Communications
ja.plaza@isciii.es
918227196 / 669187384

If you are the contact person for this centre and you wish to make any changes, please contact us.

SMC participants

Director of the National Centre for Tropical Medicine (CNMT) at the Carlos III Health Institute

PhD in Pharmacy, Professor of Human Physiology at the University of Navarra, member of the CIBER Physiopathology of Obesity, Carlos III Health Institute and IDISNA (Navarra)

Head of the Influenza and other Respiratory Virus Surveillance Group of the National Epidemiology Centre.

Researcher at the Reference and Research Laboratory in Mycology, National Microbiology Centre, Instituto de Salud Carlos III

Senior Scientist at the Health Institute Carlos III

HIV, STI and hepatitis B and C Surveillance Unit. National Centre of Epidemiology, Health Institute Carlos III

Researcher in social epidemiology, public health and biostatistics 

Researcher with a PhD employed at the National Epidemiology Centre of the Carlos III Health Institute (ISCIII)

Senior scientist at the Carlos III Health Institute

Senior Scientist at the Special Pathogens Research and Reference Laboratory of the National Microbiology Centre of the Carlos III Health Institute

Contents related to this centre
Vaccine

A study of more than 700,000 people in Sweden analysed the effectiveness of the heterologous schedule, combining the AstraZeneca vaccine with another dose of a messenger RNA vaccine, with the traditional homologous schedule, consisting of two doses of AstraZeneca. The results showed increased protection against SARS-CoV-2 infection when two different vaccines were combined.